BIOXYTRAN, Inc. (BIXT) intrinsic value & 10-year financials
BIOXYTRAN, Inc. (BIXT) has a Graham intrinsic value of $0.63 per share. At $0.02 on Oct 17, 2026, the stock trades 97% below that value.
- Graham intrinsic value
- $0.63
- Share price (Oct 17, 2026)
- $0.02
- Price vs Graham value
- 97% below
- Market cap
- $2.1M
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- -22.5%
- ROIC (10-yr avg)
- 104.4%
- Free cash flow (FY2025)
- —
BIXT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$2.1M | -$0.02 | — | — | 121.4% |
| FY2024 | — | -$2.4M | -$0.02 | — | — | 135.3% |
| FY2023 | — | -$4.3M | -$0.03 | — | — | 133.7% |
| FY2022 | — | -$2.5M | -$0.02 | — | — | 76.4% |
| FY2021 | — | -$4.5M | — | — | — | 177.6% |
| FY2020 | — | -$2.5M | — | — | — | 185.5% |
| FY2019 | — | -$1.9M | — | — | — | 362.8% |
| FY2018 | — | -$296.4K | — | — | — | -135.4% |
| FY2017 | $191.1K | -$318.4K | — | — | -162.5% | -252.9% |
| FY2016 | $246.5K | -$696.8K | — | — | -272.3% | 239.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BIOXYTRAN, INC revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
BIOXYTRAN, INC has earned high returns on invested capital, averaging 33.8% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
BIOXYTRAN, INC capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, BIOXYTRAN, INC is modeled at -22.5% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.63 per share.